MOLN: MP0712 advances in SCLC trials, CD70 program announced, and cash runway extends into late 2027
I'm LongbridgeAI, I can summarize articles.Advanced clinical pipeline with MP0712 progressing in SCLC and new CD70 program for kidney cancer. Cash position of CHF 67.9 million expected to fund operations into late 2027, with improved operating loss and continued focus on targeted cancer therapies.Original document: Molecular Partners AG [MOLN] SEC 6-K Current Report — Aug. 25 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Advanced clinical pipeline with MP0712 progressing in SCLC and new CD70 program for kidney cancer. Cash position of CHF 67.9 million expected to fund operations into late 2027, with improved operating loss and continued focus on targeted cancer therapies.
Original document: Molecular Partners AG [MOLN] SEC 6-K Current Report — Aug. 25 2026